Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 98Carcinoma, Non-Small-Cell Lung 32Neoplasms 22Neoplasm Metastasis 14Carcinoma, Renal Cell 13Prostatic Neoplasms 12Lung Neoplasms 12Small Cell Lung Carcinoma 10Diabetes Mellitus, Insulin-Dependent, 12 10Pancreatic Neoplasms 7Uveal Melanoma 6Skin Neoplasms 6Ovarian Neoplasms 6Brain Neoplasms 6Advanced Cancer 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Mesothelioma 5Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Kidney Neoplasms 4Hodgkin Disease 4Head and Neck Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Merkel Cell 4Carcinoma, Hepatocellular 4Carcinoma 4Breast Neoplasms 4Various Advanced Cancer 3

Interventions

Fluorouracil 3Radiotherapy 2Cisplatin 2Cetuximab 2rocakinogene sifuplasmid 1durvalumab 1VGX-3100 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Nivolumab 1Mitomycin 1Magnetic Resonance Spectroscopy 1MEDI0457 1Ipilimumab 1Immunoglobulin G 1Disulfides 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anal Canal Carcinoma × Ipilimumab × Clear all
NCT02314169 2026-05-28

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
143 enrolled 16 charts
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡